Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $24.9552W HIGH $52.24
Volume
91.75 K
Value Traded
9.48 M
Short % Float
17.67%
+4.09%Week
+3.94%1 Month
+15.35%3 Month
+68.08%6 Month
-21.81%5 Year
-95.55%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
917.06 M
EPS (TTM)
17.23
P/E Ratio
2.85
Ent. Value
821.73 M
Total Shares
18.50 M
Float Shares
18.06 M
Insiders
3.32%
Institutions
88.64%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
RIGL Catalyst Timeline
Dated clinical, regulatory and corporate events for Rigel Pharmaceuticals, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Rigel Pharmaceuticals, Inc.
923Total events
6Upcoming
204Tier-1 (high impact)
2009 to 2028Coverage
Upcoming catalysts 2
Event history 50
▲Product LaunchVEPPANUApprovedPost-Market
VEPPANU now available by prescription in the US
ER+/HER2-, ESR1-mutated advanced or metastatic breast cancersource ↗
▲Product LaunchVEPPANUApprovedPost-Market
VEPPANU expected to be commercially available in the U.S.
ER+/HER2-, ESR1-mutated advanced or metastatic breast cancersource ↗
▲PublicationR835Presentation
Publication of R835 preclinical and Phase 1 data in Scientific Reports
◆Poster PresentationREZLIDHIAApprovedPresentation
Real-world treatment patterns and outcomes with olutasidenib after venetoclax in IDH1-mutated AML using EHR data presented as poster at EHA 2026
relapsed or refractory mIDH1 acute myeloid leukemiasource ↗
▲Partnership / LicenseVEPPANUApprovedCorporate
Rigel entered into exclusive global licensing agreement with Arvinas and Pfizer for VEPPANU
ER+/HER2-, ESR1-mutated advanced or metastatic breast cancersource ↗
◆Poster PresentationREZLIDHIAApprovedPresentation
Long-term response characteristics to olutasidenib in AML presented as poster at ASCO 2026
relapsed or refractory mIDH1 acute myeloid leukemiasource ↗
●Oral PresentationpralsetinibApprovedPresentation
Final data from Phase 3 AcceleRET-Lung presented at ASCO
RET fusion-positive non-small cell lung cancer (NSCLC)source ↗
●Poster PresentationpralsetinibApprovedPresentation
Poster presentations for pralsetinib at ASCO and EHA
RET fusion-positive non-small cell lung cancer (NSCLC)source ↗
●Poster PresentationOlutasidenibApprovedPresentation
Poster presentations for olutasidenib at ASCO and EHA
R/R IDH1-mutated acute myeloid leukemia (AML)source ↗
◆Poster PresentationGAVRETOApprovedPresentation
Final analysis of pralsetinib in advanced or metastatic RET-altered thyroid cancer from ARROW study presented as poster at ASCO 2026
RET-altered thyroid cancersource ↗
◆Oral PresentationGAVRETOApprovedPresentation
Final data from Phase 3 AcceleRET-Lung trial of pralsetinib as first-line treatment of RET fusion-positive NSCLC presented in oral session at ASCO 2026
RET fusion-positive non-small cell lung cancersource ↗
◆Oral PresentationPresentation
Rigel presents company overview at 2026 RBC Capital Markets Global Healthcare Conference
▲Partnership / LicenseVEPPANUApprovedCorporate
Rigel enters exclusive global license agreement for VEPPANU from Arvinas and Pfizer
ER+/HER2-, ESR1m mBCsource ↗
▲Milestone PaymentVEPPANUApprovedCorporate
Upfront payment of $70M and potential $15M transition milestone
▲Other Regulator MilestonevepdegestrantFiledEx-US Regulatory
NCCN Guidelines added vepdegestrant as Category 2A treatment option
HR+/HER2-, ESR1-mutated advanced or metastatic breast cancersource ↗
▲FDA ApprovalVEPPANUApprovedFDA Decision
FDA approval of VEPPANU
ER+/HER2-, ESR1-mutated advanced or metastatic breast cancersource ↗
▲Other Regulator MilestoneTAVALISSEApprovedEx-US Regulatory
ANVISA approval for TAVALISSE in Brazil
chronic immune thrombocytopenia (ITP)source ↗
▲Product LaunchTAVALISSEApprovedPost-Market
Knight commercially launched TAVALISSE in Mexico
chronic immune thrombocytopenia (ITP)source ↗
●NDA SubmissionOlutasidenibApprovedRegulatory Filing
Kissei submitted NDA for olutasidenib in Japan
isocitrate dehydrogenase-1 (IDH1)-mutated acute myeloid leukemia (AML)source ↗
▲Partnership / LicenseVEPPANUApprovedCorporate
Exclusive global license agreement with Arvinas and Pfizer
▲Enrollment CompleteR289Trial
Phase 1b study of R289 expected to complete enrollment in dose expansion
relapsed or refractory lower-risk myelodysplastic syndrome (MDS)source ↗
◆Dose Finding UpdateR289Trial
Selection of recommended Phase 2 dose for R289 expected
relapsed or refractory lower-risk myelodysplastic syndrome (MDS)source ↗
▲Milestone PaymentOlutasidenibApprovedCorporate
Rigel received $4.0M regulatory milestone from Kissei
isocitrate dehydrogenase-1 (IDH1)-mutated acute myeloid leukemia (AML)source ↗
▲Full ResultsGAVRETOApprovedClinical Data
Publication of final ARROW clinical trial data in Journal of Clinical Oncology
RET fusion-positive non-small cell lung cancersource ↗
◆Quarterly UpdateCorporate
Q4 and full year 2025 financial results and business update conference call
◆Enrollment UpdateR289Trial
Phase 1b study of R289 in lower-risk MDS continues enrollment
lower-risk MDSsource ↗
◆Oral PresentationPresentation
Rigel presents at 44th Annual J.P. Morgan Healthcare Conference
▼FDA ApprovalGAVRETOApprovedFDA Decision
FDA approved Prior Approval sNDA adding boxed warning for serious infections
RET fusion-positive NSCLC and thyroid cancersource ↗
◆Poster PresentationREZLIDHIAApprovedPresentation
Poster presentation on olutasidenib monotherapy in patients with mIDH1 AML who received prior intensive chemotherapy
relapsed/refractory mIDH1 acute myeloid leukemia (AML)source ↗
◆Oral PresentationR289Presentation
Oral presentation of updated safety and efficacy results from Phase 1b study of R289 in R/R LR-MDS at ASH 2025
lower-risk myelodysplastic syndrome (MDS) relapsed or refractorysource ↗
◆Poster PresentationREZLIDHIAApprovedPresentation
Poster presentation on real-world treatment patterns and outcomes of olutasidenib in patients previously treated with venetoclax
relapsed/refractory mIDH1 acute myeloid leukemia (AML)source ↗
◆Poster PresentationREZLIDHIAApprovedPresentation
Poster presentation on clinical characteristics and response in olutasidenib-treated R/R mIDH1 AML patients with stable disease after two cycles
relapsed/refractory mIDH1 acute myeloid leukemia (AML)source ↗
◆Oral PresentationPresentation
Rigel presents at Piper Sandler 37th Annual Healthcare Conference
▲Oral PresentationR289Presentation
Updated dose escalation data presented at ASH 2025
lower-risk myelodysplastic syndrome (MDS)source ↗
●Poster PresentationOlutasidenibApprovedPresentation
Four posters on olutasidenib presented at ASH 2025
relapsed/refractory mIDH1 AMLsource ↗
▲Poster PresentationpralsetinibApprovedPresentation
Sub-analysis data from ARROW study presented at NACLC 2025
RET fusion-positive NSCLCsource ↗
◆Oral PresentationPresentation
Rigel presents at Jefferies Global Healthcare Conference in London
▲PublicationREZLIDHIAApprovedPresentation
Publication of final 5-year data from pivotal cohort of Phase 2 trial of olutasidenib in R/R mIDH1 AML
relapsed or refractory mutant IDH1 acute myeloid leukemiasource ↗
▲Trial InitiationOlutasidenibApprovedTrial
Phase 2 trial of olutasidenib in R/R IDH1-mutated myeloid malignancies initiated
relapsed/refractory IDH1-mutated myeloid malignanciessource ↗
▲Enrollment CompleteR289Trial
Enrollment complete in dose escalation phase of Phase 1b study of R289 in lower-risk MDS
lower-risk MDSsource ↗
Past FDA Catalysts and PDUFA Decisions
How RIGL actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-05-29 | GAVRETO (pralsetinib) | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C40 / 100
Pipeline Score
$57M
Pipeline Value
$631M
Commercial Value
Fair Value
Valuation Signal
3
Drugs Scored
0.2x
rNPV / MCap
Top 40%
Micro Cap(rank 264 of 658)
Percentile Rank
Rigel Pharmaceuticals, Inc. carries a moderate pipeline score (40/100), with $143M risk-adjusted pipeline value, led by Fostamatinib in Acute Respiratory Distress Syndrome (Phase 2).
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Jun 2026; product lines: last four quarters to Jun 2026 (10-K and 10-Q)) Revenue $276.8M x 2.3 = $631M
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| TAVALISSE | $175M | $126M | +39.1% |
| GAVRETO | $42M | $36M | +15.6% |
| REZLIDHIA | $35M | $26M | +33.7% |
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Fostamatinib Small moleculeNCT02612558 | Warm Antibody Autoimmune Hemolytic Anemia | Phase 3 | COMPLETED | 206 | Dec 1, 2019 |
Clinical Trial Results
Readouts, endpoints and source filings for every RIGL program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| vepdegestrant | 2L+ ER+/HER2-, ESR1m Advanced or Metastatic Breast Cancer | Phase 3 | 2026-05-12 | mPFS of 5.0 months vs. 2.1 months for fulvestrant, a 2.4-fold improvementRead More | Rigel Enters Exclusive Global Licensing Agreement for VEPPANU™ (vepdegestrant), an oral PROTAC, for the Treatment of 2L+ ER+/HER2-, ESR1m Advanced or Metastatic Breast CancerRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Schorno Dean LOfficer (EVP & Chief Financial Officer) | Option | 694 79,056 held | $12.70 | 09/02/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in RIGL
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| SOLEUS CAPITAL MANAGEMENT, L.P. | 2.5 % (400 %) | 72.12 M | 1.84 M | 514.43% ( 1.54 M) |
RIGL Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How RIGL ranks across every disease it competes in
Competitive Position is a premium feature
See how RIGL ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialRIGL News
RIGLRigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Rigel Pharmaceuticals, Inc. announced the grant of 35,275 restricted stock units to 18 non-executive employees as part of its Inducement Plan. This initiative, approved by the Compensation Committee, aims to attract new talent in accordance with NASDAQ Listing Rule 5635(c)(4). The stock units will vest over four years, promoting employee retention.
Read more →RIGLRigel to Participate in Upcoming September Investor Conferences
Rigel Pharmaceuticals announced its participation in several investor conferences in September 2026. CFO Dean Schorno will engage in one-on-one meetings and present company overviews at the Citi, Cantor, and H.C. Wainwright conferences. These events aim to foster investor relations and showcase Rigel's advancements in hematologic disorders and cancer treatments.
Read more →RIGLRigel Announces Availability of VEPPANU™ (vepdegestrant) for Patients with ER+/HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer
Rigel Pharmaceuticals has announced the availability of VEPPANU (vepdegestrant), the first FDA-approved PROTAC for treating advanced or metastatic breast cancer with specific mutations. This new treatment option is aimed at patients who have progressed after at least one line of endocrine therapy. VEPPANU has shown significant improvement in progression-free survival compared to existing therapies. The drug is now available through specialty pharmacies at a cost of $29,400 for a 30-day supply.
Read more →RIGLRigel Reports Second Quarter 2026 Financial Results
Rigel Pharmaceuticals reported strong financial results for Q2 2026, with total revenues of $78.7 million, including net product sales of $67 million. The company expanded its commercial portfolio by in-licensing VEPPANU, an FDA-approved PROTAC for breast cancer. Despite a decrease in net income compared to the previous year, Rigel remains on track with its clinical programs, particularly the R289 development in lower-risk MDS.
Read more →RIGLRigel Announces Conference Call and Webcast to Report Second Quarter 2026 Financial Results
Rigel Pharmaceuticals has announced a conference call and webcast to discuss its second quarter 2026 financial results. The results will be reported after market close on August 4, 2026, followed by a live discussion at 4:30 p.m. ET. The event will be accessible via phone and webcast, with an archive available for 90 days.
Read more →RIGLRigel Appoints Board Member Alison L. Hannah, M.D. as Chief Medical Officer
Rigel Pharmaceuticals has appointed Dr. Alison L. Hannah as Chief Medical Officer, effective July 1, 2026. Dr. Hannah, who has served on Rigel's Board since 2021, resigns from her board position to take on this executive role. She brings significant experience in oncology and will lead the development of Rigel's pipeline, including investigational therapies for hematologic disorders and cancer.
Read more →RIGLRigel Announces Closing of Licensing Agreement for VEPPANU™ (vepdegestrant)
Rigel Pharmaceuticals has finalized a licensing agreement for VEPPANU (vepdegestrant), an FDA-approved treatment for advanced breast cancer. The agreement, effective June 11, 2026, includes a $70 million upfront payment to Arvinas and Pfizer. Rigel plans to make VEPPANU commercially available by August 2026, despite potential risks associated with its use.
Read more →RIGLRigel to Present at the Jefferies Global Healthcare Conference
Rigel Pharmaceuticals, Inc. will present an overview at the Jefferies Global Healthcare Conference on June 3, 2026. CEO Raul Rodriguez will lead the presentation, showcasing the company's focus on hematologic disorders and cancer. Interested parties can access the live webcast through Rigel's website.
Read more →RIGLRigel Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting and EHA2026 Congress
Rigel Pharmaceuticals announced that it will present final data from the Phase 3 AcceleRET-Lung trial for GAVRETO at the 2026 ASCO Annual Meeting. Additionally, the company will showcase further data on pralsetinib and REZLIDHIA at both the ASCO and EHA 2026 Congress. These presentations emphasize Rigel's commitment to enhancing treatment options for patients with hematologic disorders and cancer.
Read more →RIGLRigel to Present at the 2026 RBC Capital Markets Global Healthcare Conference
Rigel Pharmaceuticals announced that CFO Dean Schorno will present at the 2026 RBC Capital Markets Global Healthcare Conference. The presentation is scheduled for May 19 at 9:30 a.m. ET in New York. This event reflects Rigel's commitment to engaging with the investment community and discussing its advancements in hematologic disorders and cancer treatments.
Read more →RIGL▲ +12.1%on this news· ran to +23% by day 1shared move
Rigel Enters Exclusive Global Licensing Agreement for VEPPANU™ (vepdegestrant), an oral PROTAC, for the Treatment of 2L+ ER+/HER2-, ESR1m Advanced or Metastatic Breast Cancer
Rigel Pharmaceuticals has entered an exclusive global licensing agreement with Arvinas and Pfizer to develop and commercialize VEPPANU (vepdegestrant), the first FDA-approved oral PROTAC, targeting advanced or metastatic breast cancer. The drug showed a significant 2.4-fold improvement in progression-free survival compared to the standard treatment, fulvestrant, during the Phase 3 VERITAC-2 trial. Rigel expects VEPPANU to substantially contribute to revenue growth and fill an important gap in treatment for patients with ESR1 mutations who have limited options following endocrine therapy. The agreement is set to close in mid-June 2026, pending regulatory clearance.
Read more →RIGL▼ -5.1%on this news
Rigel Reports First Quarter 2026 Financial Results
Rigel Pharmaceuticals reported strong financial results for Q1 2026, with total revenues of $58.8 million, a 26% increase from the previous year. The company achieved profitability with a net income of $8.7 million, although this was lower than the prior year's figure. Rigel continues to advance its clinical development pipeline, particularly the R289 study for lower-risk MDS, while maintaining a solid cash position.
Read more →RIGLRigel Announces Conference Call and Webcast to Report First Quarter 2026 Financial Results
Rigel Pharmaceuticals will announce its first quarter 2026 financial results on May 5, 2026, after market close. Following the announcement, senior management will host a live conference call and webcast at 4:30 p.m. ET to discuss the results and provide a business update. The call will be accessible via phone and webcast, with a replay available for 90 days.
Read more →RIGL▲ +5.1%on this news
Rigel Announces Publication of Final ARROW Clinical Trial Data on GAVRETO® (pralsetinib) in Patients with RET+ NSCLC in the Journal of Clinical Oncology
Rigel Pharmaceuticals announced the publication of final data from the Phase 1/2 ARROW study on pralsetinib for treating RET fusion-positive NSCLC. The results indicate a 70% overall response rate and emphasize the drug's manageable safety profile. The findings support pralsetinib's potential as a first-line treatment option, particularly for patients with measurable CNS metastases.
Read more →RIGL▼ -10.3%on this news
Rigel Provides Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Rigel Pharmaceuticals reported strong financial results for Q4 and full year 2025, with record net product sales and a significant increase in net income. The company highlighted its progress in clinical development, particularly with the R289 program for lower-risk MDS. Rigel anticipates continued growth and positive net income for 2026, despite rising costs associated with R&D efforts.
Read more →RIGLRigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2025 Financial Results and Business Update
Rigel Pharmaceuticals will announce its fourth quarter and full year 2025 financial results on March 3, 2026. Following the announcement, a live conference call and webcast will be held at 4:30 p.m. ET to discuss the results and provide a business update. The call will be accessible via phone and webcast, with an archived version available for 90 days.
Read more →RIGLRigel Appoints Michael P. Miller to the Board of Directors
Rigel Pharmaceuticals has appointed Michael P. Miller to its Board of Directors. With over 40 years in the biotech and pharmaceutical sectors, Miller's experience is expected to enhance Rigel's strategic initiatives. He has previously held significant roles at Jazz Pharmaceuticals and Genentech, among others, and is eager to contribute to Rigel's mission in hematologic disorders and cancer.
Read more →About Rigel Pharmaceuticals, Inc.
Headquarters611 GATEWAY BOULEVARD, SUITE 900, SOUTH SAN FRANCISCO, CA, 94080
BIOPHARMAWATCH ELITE PLUS
Trade the next RIGL catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime